Previous 10 | Next 10 |
2023-08-18 06:51:30 ET More on Calliditas Calliditas: Riding The Setanaxib Wave And Betting On Tarpeyo's Triumph Calliditas Therapeutics: First Quarter Not As Bad As It Looks Calliditas interim phase 2 data positive for head and neck cancer asset setanaxib Ca...
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy PR Newswire STOCKHOLM , Aug. 18, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT), (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the ...
Everest Medicines' Partner Calliditas Therapeutics Announces Full Results From NefIgArd Phase 3 Trial published in The Lancet PR Newswire SHANGHAI , Aug. 17, 2023 /PRNewswire/ -- Everest Medicines' (HKEX 1952.HK, "Everest", or the "Company") partner Calliditas Th...
Interim Report Q2, 2023: Calliditas Therapeutics PR Newswire Filing for full approval of TARPEYO STOCKHOLM , Aug. 17, 2023 /PRNewswire/ -- FINANCIAL SUMMARY FOR THE GROUP Key Figures April 1 - June 30, 2023 Net sales amounted...
Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet PR Newswire STOCKHOLM , Aug. 15, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced ...
2023-07-20 18:36:07 ET Summary We maintain a buy rating due to promising interim data from the Phase II trial of setanaxib in patients with squamous cell carcinoma of the head and neck and potential Q2 earnings from Tarpeyo's sales. Despite promising interim data, the market has y...
Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib PR Newswire STOCKHOLM , July 13, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Cal...
2023-06-25 05:45:00 ET Summary AstraZeneca may separate its China operations into a standalone company and conduct an IPO in Hong Kong or Shanghai to protect its business from east-west political tensions. Cutia Therapeutics, a Shanghai dermatology company, raised $65 million in a...
Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO® PR Newswire STOCKHOLM , June 21, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX)...
2023-05-31 12:07:41 ET Summary Shares of Calliditas Therapeutics plunged after the company missed Q1 revenue estimates. The quarter was better than it looks and the company saw record new patient enrollments for Tarpeyo. It was also too early for the recently reported 2-year e...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB Company Name:
CALT Stock Symbol:
NASDAQ Market:
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatri...
2024-06-30 09:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Calliditas provides setanaxib patent update PR Newswire STOCKHOLM , June 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) h...